Lyda Hill Philanthropies committed $3 million to nonprofit pharmaceutical company NP2 to help commercialize its first U.S.-manufactured generic oncology drug and reduce the cost of cancer treatments. The funding combines philanthropic support with milestone-based loan capital and will accelerate development of cyclophosphamide, a widely used chemotherapy drug, while strengthening the domestic supply chain for essential cancer medicines. The investment reflects Lyda Hill Philanthropies' commitment to advancing innovative healthcare solutions that improve affordability, expand patient access, and foster sustainable models for drug development.